Gyre Therapeutics, Inc. GYRE Gyre — Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s gyre — operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s gyre — operating income?
- Gyre Therapeutics, Inc. (GYRE) reported gyre — operating income of -$6.28M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s gyre — operating income changed year-over-year?
- Gyre Therapeutics, Inc.'s gyre — operating income decreased by 329.7% year-over-year, from -$1.46M to -$6.28M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s gyre — operating income?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre — operating income has grown at a -69.0% compound annual growth rate (CAGR), from -$88.4M to -$8.49M.
- What does gyre — operating income mean?
- This represents the profit or loss generated by the segment after subtracting operating expenses from its gross profit. It measures the core operational profitability of the business unit before accounting for interest, taxes, or non-operating items. A positive value indicates a self-sustaining business model, while a negative value highlights the need for external funding or future revenue growth.